- ‹ Back
- Our Team
- About Depression
- What is TMS Therapy?
- Contact Us
8:30am-5pm M-Th, and 8:30am-noon Friday
105 N Lyndon Ln Suite 106
Louisville, KY 40222
(Your identity will be kept confidential)
In March, 2001, Integrative Psychiatry was established as a private, outpatient practice, dedicated to providing a holistic and integrated treatment program for each individual. In this setting, cutting edge medical therapies such as advanced psychopharmacology and transcranial magnetic stimulation (TMS) are combined with other evidenced based treatments including:
Since May, 2010, we have offered Neurostar® TMS Therapy to our patients, and have developed into the most experienced TMS practice in this region of the country. Transcranial Magnetic Stimulation Therapy is one of the more technologically advanced depression treatments available. This non-invasive, outpatient therapy is FDA cleared and has helped thousands of depression patients who have not received adequate results from antidepressants. TMS uses highly focused, pulsed magnetic stimulation to restore normal brain function in the prefrontal cortex. TMS is well-tolerated, with few adverse effects. In particular, there are no systemic effects. Patients remain fully awake during the 37-minute treatment sessions, and are able to resume their daily activities immediately. Doctor Schrodt was featured on WLKY-TV talking about the benefits of TMS. See the full news story here.
Integrative Psychiatry has recently completed a study on the benefits of TMS with treatment resistant depressed patients in their practice. The findings were published in the September, 2011, issue of the Journal of the Kentucky Medical Association. Read the full article here.
Integrative Psychiatry was also one of 42 clinical practice sites (both university and private practice) that participated in the “real world setting” study of TMS that was presented at the American Psychiatric Association 2013 Annual Meeting. In this naturalistic, observational study of TMS, acute response and remission rates were similar to those observed in previous research populations. The study also found that the antidepressant benefits were maintained throughout the following year (at times with medication, psychotherapy, or further TMS treatments). At one year follow-up, 68% of patients that began treatment with TMS were classified as responders (at least 50% improvement in depression scores), and 45% had full remission of depressive symptoms. The long-term durability of improvement with transcranial magnetic stimulation in treatment-resistant depressed patients is substantially higher than that observed with other conventional depression therapies, including medication and electroconvulsive therapy (ECT).
Integrative Psychiatry has been selected to be a research site for a new study on the use of TMS for postpartum depression. Postpartum depression (PDD) has been reported in 10-15% of women following delivery. It is the most common complication of childbirth, and 20% of deaths in the postpartum period are due to suicide. PDD is strongly associated with lower quality of maternal-infant bonding, early discontinuation of breastfeeding, higher risk of impaired cognitive and emotional development in the child, as well as negative impact on other members of the family. Although antidepressant medications are commonly used in the treatment of PPD, they are usually excreted in breast milk. Many nursing mothers wish to avoid exposing their infants to these antidepressants, and the unknown future effects. In addition, a significant number of depressed women do not adequately respond to antidepressant medication, and many experience intolerable side effects. Transcranial magnetic stimulation is unique compared to other somatic therapies for depression because there are no systemic side effects that would interfere with child care, and no risk of exposure to the infant through breastfeeding.